Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
04/2010
04/27/2010CA2422378C Pyrazole compounds useful as protein kinase inhibitors
04/27/2010CA2387719C Azaindolizinone derivatives and cognitive enhancers comprising the same as effective components
04/27/2010CA2354213C N-triazolylmethyl-piperazine compounds with neurokinin-receptor antagonist activity
04/27/2010CA2350246C Controlled delivery of active agents
04/27/2010CA2338968C Glucocorticoid-selective agents
04/27/2010CA2323776C Cytokine receptor common gamma chain like
04/27/2010CA2321926C Use of rhamnolipids in a composition for the treatment of signs of aging
04/27/2010CA2297998C Aqueous solution for use in the treatment of degenerative or autoimmune diseases and as an immunomodulatory agent
04/22/2010WO2010045577A2 Extracts of curcuma and methods of use thereof
04/22/2010WO2010045575A2 Compositions and methods for treatment of renin-angiotensin aldosterone system (raas)-related disorders
04/22/2010WO2010045251A2 Spiro-oxindole compounds and their use as therapeutic agents
04/22/2010WO2010045212A2 Nicotinic acetylcholine receptor ligands and the uses thereof
04/22/2010WO2010045197A1 Spiro-oxindole compounds and their use as therapeutic agents
04/22/2010WO2010045190A1 Fused heteroaryl diamide compounds useful as mmp-13 inhibitors
04/22/2010WO2010045166A1 Heterocyclic benzimidazoles as trpm8 modulators
04/22/2010WO2010045017A1 Amines and sulfoxides of thieno [2,3-d] pyrimidine and their use as adenosine a2a receptor antagonists
04/22/2010WO2010045016A1 Heterocyclyl and cycloalkyl substituted thieno [2,3-d] pyrimidine and their use as adenosine a2a receptor antagonists
04/22/2010WO2010045015A1 Heteroaryl substituted thieno[2,3-d]pyrimidine and their use as adenosine a2a receptor antagonists
04/22/2010WO2010045013A1 Phenyl substituted thieno [2,3-d] pyrimidines and their use as adenosine a2a receptor antagonists
04/22/2010WO2010045012A1 Heteroaryl and phenyl substituted thieno [2,3-d] pyrimidines and their use as adenosine a2a receptor antagonists
04/22/2010WO2010045009A1 PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d] PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
04/22/2010WO2010045008A1 AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
04/22/2010WO2010045006A1 Methylene amines of thieno [2,3-d] pyrimidine and their use as adenosine a2a receptor antagonists
04/22/2010WO2010044981A2 Benzoquinoline inhibitors of vesicular monoamine transporter 2
04/22/2010WO2010044917A1 Compositions for the prevention and treatment of neuroinjury and methods of use thereof
04/22/2010WO2010044878A1 Methods and compositions for improving cognitive function
04/22/2010WO2010044743A1 Novel thiophene compounds for use in theraphy
04/22/2010WO2010044736A1 Multi portion intra-oral dosage form and use thereof
04/22/2010WO2010044464A1 Modified amyloid beta peptide
04/22/2010WO2010044016A1 Novel uses for esreboxetine and racemic reboxetine
04/22/2010WO2010043867A1 Pyrrolo [2, 3-d] pyrimidines as inhibitors of hsp90
04/22/2010WO2010043866A2 Histone lysine demethylase inhibitors
04/22/2010WO2010043865A1 Inhibitors of hsp90
04/22/2010WO2010043787A1 Use of 4-(3-[hexahydrocyclopenta[c]pyrrol-i(1h)-yl]propoxy}benzamide for making drugs for treating sleep disorders
04/22/2010WO2010043631A1 Di-vanilloyl and tri-vanilloyl derivatives for use in anti-cancer therapy
04/22/2010WO2010043561A2 Regenerative therapy
04/22/2010WO2010043539A1 Novel oxadiazolyl-diazabicyclononane derivatives and their medical use
04/22/2010WO2010043412A1 Co-crystals of tramadol and nsaids
04/22/2010WO2010043396A1 Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
04/22/2010WO2010043240A1 Administration scheme of polar opioid metabolites for post-operative pain management
04/22/2010WO2010043076A1 A method for constructing human placental mesenchymal cells library which is suitable for clinical application
04/22/2010WO2010017912A3 Use of human hyaluronidases for axonal regrowth
04/22/2010WO2010014613A3 Treating various disorders using trkb agonists
04/22/2010WO2010012904A3 Novel cholest-4-en-3-one oxime derivatives, pharmaceutical compositions containing same, and preparation method
04/22/2010WO2010009120A3 Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
04/22/2010WO2010005580A3 Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
04/22/2010WO2010005528A3 Pyrrolopyridine carboxylic acid derivatives
04/22/2010WO2010004031A3 Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist
04/22/2010WO2009158309A3 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
04/22/2010WO2009156680A3 Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders
04/22/2010WO2009155932A3 Modulation of the trpv : vps10p-domain receptor system for the treatment of pain
04/22/2010WO2009129545A8 Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
04/22/2010WO2009043450A8 Use of neurotrophic factor for retinal cholinergic neurons (nfrcn) and chorionic gonadotropin-beta (109-145) as therapeutic agents
04/22/2010WO2008047241A3 Modified corticotropin releasing factor peptides and uses thereof
04/22/2010US20100100978 RNAi MEDIATED EXPRESSION INHIBITION OF A CHOLINERGIC PROTEIN
04/22/2010US20100099775 Method for ameliorating of post-anesthetic recovery
04/22/2010US20100099773 Inclusion complex of sibutramine and beta-cyclodextrin
04/22/2010US20100099772 Methods, compositions, and kits for treating pain and pruritis
04/22/2010US20100099770 Method for treating diabetic peripheral neuropathic pain
04/22/2010US20100099768 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
04/22/2010US20100099763 Triterpene compounds which are effective on improvement of brain function
04/22/2010US20100099762 Combination therapy
04/22/2010US20100099761 Levodopa Prodrug Mesylate Hydrate
04/22/2010US20100099760 Glycyrrhetinic Acid Derivatives
04/22/2010US20100099756 Uses of incensole, incensole acetate and derivatives thereof
04/22/2010US20100099752 Pharmaceutical composition containing bicyclic type compounds
04/22/2010US20100099749 Nucleic Acid Inhibitors Of Glutamate Receptors
04/22/2010US20100099747 Reduction of polyalanine-induced protein aggregates and toxicity by ubiquilin
04/22/2010US20100099741 Molecular Targets for Treatment of Learning and Memory Dysfunction
04/22/2010US20100099736 Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting mpt
04/22/2010US20100099735 Methods and compositions for improving cognitive function
04/22/2010US20100099731 Use of Endothelial Interrupters in the Treatment of Neurodegenerative Diseases
04/22/2010US20100099729 Nitric oxide donor compounds
04/22/2010US20100099728 Spiro-oxindole compounds and their use as therapeutic agents
04/22/2010US20100099721 Novel compounds for the treatment of neurological disorders
04/22/2010US20100099715 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mglur2-receptor modulators
04/22/2010US20100099714 AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
04/22/2010US20100099709 Pyridin-2-yl-methylamine derivatives for treating opiate dependence
04/22/2010US20100099703 Phenylamino-substituted piperidine compounds, their preparation and use as medicaments
04/22/2010US20100099699 Peripheral opioid receptor antagonists and uses thereof
04/22/2010US20100099696 Tamper resistant oral dosage forms containing an embolizing agent
04/22/2010US20100099691 Pyrimidinyl pyridone inhibitors of jnk
04/22/2010US20100099684 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands
04/22/2010US20100099678 Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders
04/22/2010US20100099667 Bridged heterocyclic compounds and methods of use
04/22/2010US20100099666 Phenothiazine modulators of h1 receptor and d2 receptor
04/22/2010US20100099662 Hydrazone derivative
04/22/2010US20100099657 Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity
04/22/2010US20100099656 Neurotherapeutic compositions
04/22/2010US20100099645 Compositions containing pufa and methods of use thereof
04/22/2010US20100099642 Tgf-beta stimulant and further agent to reduce side effects
04/22/2010US20100099617 Secreted proteins
04/22/2010US20100099609 eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE
04/22/2010US20100099608 Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
04/22/2010US20100099607 Casein complexes
04/22/2010US20100098788 Extracts of Curcuma and Methods of Use Thereof
04/22/2010US20100098774 Composition comprising crustacean gastrolith components and its use
04/22/2010US20100098771 Abuse-resistant oral dosage forms and method of use thereof
04/22/2010US20100098757 Process for production of buprenorphine pharmaceutical preparation to be applied to mouth mucosa
04/22/2010US20100098714 Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
1 ... 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 ... 1833